Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) used as a research compound for studying the growth hormone secretagogue receptor, also called GHS-R1a. The main early study tested ipamorelin in rat pituitary cells, anesthetized rats, and conscious swine.[1]

The NCI Drug Dictionary describes ipamorelin as a ghrelin mimetic that binds to GHSR and selectively stimulates GH release from the pituitary gland.[3]
The word selective has a narrow meaning here. It refers to the hormones measured in specific laboratory experiments—namely, GH release without statistically significant ACTH or cortisol elevation in the tested models.
It does not mean that every possible effect, target, tissue, or long-term risk has been tested.
Molecular Profile
| Item | Ipamorelin Free Base | Ipamorelin Acetate (where supplied) |
|---|---|---|
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | |
| Peptide length | Five residues | |
| CAS Registry Number | 170851-70-4 | 1258196-85-8 |
| Molecular formula | C38H49N9O5 | C38H49N9O5 · xCH3COOH; x may vary |
| Average molecular weight | Approximately 711.9 g/mol | Depends on acetate equivalents |
| Monoisotopic mass | 711.3857 Da[2] | Not applicable to the salt form as a fixed value |
| Development code | NNC 26-0161 | |
| PubChem CID | 9831659 | |
The sequence was reported in the original ipamorelin paper, and the CAS number, formula, molecular weight, monoisotopic mass, development code, and PubChem CID are listed by NCBI PubChem.[1][2]
The listed formula, average molecular weight, monoisotopic mass, and CAS 170851-70-4 refer to ipamorelin free base. Ipamorelin acetate (CAS 1258196-85-8) is a distinct salt form that may contain a variable number of acetate equivalents.
The actual salt form and counterion content must be confirmed from the batch-specific COA before molar calculations are performed. For accurate concentration work, use the lot-specific net peptide content rather than treating the full vial mass as pure free peptide.
The original development paper states that ipamorelin came from a series of compounds that lacked the central Ala-Trp pair found in GHRP-1. It should not be described as a simple one-residue deletion from GHRP-6.[1]
How It Works in Laboratory Models
GHS-R1a is a G-protein-coupled receptor first identified in pituitary and hypothalamic tissue.[4] Ghrelin was later identified as a natural acylated peptide ligand for this receptor.[5]
Studies of GHS-R1a signaling in pituitary cells show that receptor activation can involve phospholipase C, adenylate cyclase/protein kinase A, changes in intracellular calcium, and L-type voltage-sensitive calcium channels. These signals help pituitary cells release growth hormone.[6]
This is a general model of GHS-R1a signaling. The cited signaling study used ghrelin rather than ipamorelin.
The original ipamorelin paper showed a GHRP-like receptor response using GHRP and GHRH antagonists, but it did not prove that ipamorelin has a unique receptor conformation, a unique signaling pathway, or a fully characterized biased-agonism profile.[1]
Main Research Findings
Laboratory data only: The values below come from specific cell and animal experiments. EC50 and ED50 describe the concentration or dose that produced half of the maximum measured response in that experiment.
Values are reported as mean ± SEM where specified in the original study. They are not use instructions.
| Experiment | Ipamorelin result | Comparison reported in the same study |
|---|---|---|
| Primary rat pituitary cells | EC50: 1.3 ± 0.4 nmol/L Emax: 85 ± 5% |
GHRP-6 EC50: 2.2 ± 0.3 nmol/L GHRP-6 Emax: 100% reference |
| Pentobarbital-anesthetized rats | ED50: 80 ± 42 nmol/kg Emax: 1,545 ± 250 ng GH/mL |
GHRP-6 ED50: 115 ± 36 nmol/kg GHRP-6 Emax: 1,167 ± 120 ng GH/mL |
| Conscious swine | ED50: 2.3 ± 0.03 nmol/kg Emax: 65 ± 0.2 ng GH/mL plasma |
GHRP-6: ED50 3.9 ± 1.4 nmol/kg; Emax 74 ± 7 ng/mL GHRP-2: ED50 0.6 nmol/kg; Emax 56 ± 6 ng/mL |
Absolute GH Emax values should not be directly compared across species or experimental models because assay methods, baseline correction, anesthesia, sampling design, and physiological GH secretion patterns differ. The reported values for different rows in this table were obtained under different conditions and should not be treated as a single ranking.[1]
In the conscious-swine part of the study, ipamorelin, GHRP-6, and GHRP-2 did not significantly change FSH, LH, prolactin, or TSH under the tested conditions. GHRP-6 and GHRP-2 increased ACTH and cortisol.
Ipamorelin did not produce ACTH or cortisol levels that were significantly different from the GHRH comparison group, even at experimental doses more than 200 times its GH ED50.[1]
These results support a selective growth hormone response in that study. They do not prove that ipamorelin affects only growth hormone in every species, tissue, dose range, or study length.
Human Pharmacokinetic and Clinical Data
Although this article focuses on in-vitro and laboratory-animal research, ipamorelin has been studied in humans. Gobburu et al. (1999) conducted a dose-escalation PK/PD study in healthy male volunteers (eight subjects per dose level) using five intravenous infusion rates (4.21–140.45 nmol/kg over 15 minutes).
Ipamorelin showed dose-proportional pharmacokinetics with a terminal half-life of approximately 2 hours, a clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg. A single infusion produced a single episode of GH release peaking at approximately 0.67 hours.
The concentration for half-maximal GH stimulation (SC50) was 214 nmol/L, with a maximal GH production rate of 694 mIU/L/h. These data confirm that ipamorelin can stimulate GH release in humans.[11]
Ipamorelin was also evaluated in a randomized, double-blind, placebo-controlled phase 2 study in patients undergoing bowel resection (Beck et al., Ipamorelin 201 Study Group, 2014). The primary endpoint—time to first tolerated solid meal—was 25.3 hours with ipamorelin versus 32.6 hours with placebo, but this difference did not reach statistical significance (p = 0.15).[12]
These findings do not establish efficacy for muscle growth, fat loss, anti-aging, sleep improvement, bone-density treatment, or any other personal-use application. No FDA-approved drug product contains ipamorelin free base or ipamorelin acetate.
Research Areas
- Growth hormone and pituitary research: Ipamorelin can be used in controlled experiments that measure growth hormone release, pituitary-cell responses, and GHS-R1a pharmacology. Each report should clearly state the model, timing, comparison group, and measured endpoints.
- Longitudinal bone growth in rats: Johansen et al. (1999) administered ipamorelin subcutaneously three times daily for 15 days to adult female rats (0, 18, 90, and 450 μg/day). Longitudinal bone growth rate in the proximal tibia increased dose-dependently from 42 μm/day in the vehicle group to 52 μm/day at the highest dose (P < 0.0001).Body weight gain also showed a pronounced dose-dependent increase. Total IGF-I, IGF-binding proteins, and serum markers of bone formation and resorption did not change significantly.Pituitary GH content was unchanged, and the provocative GH response to ipamorelin was marginally reduced (P < 0.03) while the response to GHRH remained unchanged.[7]
- Bone mineral content in rats: A separate 12-week study reported increases in bone mineral content and bone size in young adult female rats. The researchers found that the increase was linked to larger bone dimensions, while volumetric bone mineral density and mineral concentration remained unchanged.[8]
These findings must be described as laboratory rat findings. “Higher bone mineral content” should not be rewritten as a general claim of higher bone density.
Limits of the Evidence
- The main selectivity data came from rat cells, rats, and swine.
- The main paper tested a limited group of hormones, not every possible biological effect.
- Human PK/PD data confirm GH release but do not establish long-term safety.
- A phase 2 postoperative ileus trial did not meet its primary efficacy endpoint (p = 0.15).
- The cited studies do not prove that ipamorelin has no effect on appetite or every other GHS-R1a pathway.
- The cited studies do not establish a specific multi-peptide combination protocol.
- Cell and laboratory animal findings must not be presented as human, medical, or veterinary outcomes.
Laboratory Handling and Reconstitution
Laboratory preparation only: This section concerns bench-top preparation for analytical or cell-based research. It is not an injection or personal-use guide.
Follow the batch-specific COA or a validated stability protocol. If no validated condition is available, temporary storage of unopened lyophilized material at approximately −20°C in a tightly sealed, dry, light-protected container may be used as a conservative laboratory holding condition, but it must not be presented as a validated shelf-life claim.
A fixed shelf life should not be claimed without stability data from the actual material and container.[14]
Choose a purified aqueous solvent or buffer that is compatible with the assay, salt form, target pH, and required concentration. There is no single reconstitution recipe that is correct for every lot and every method.
This article therefore does not provide a fixed milligram-per-milliliter formula.
For molar calculations, use the verified net amount of free-peptide equivalent from the COA:
Molar concentration = moles of free-peptide equivalent / final solution volume
Do not calculate moles from total vial mass alone when the material contains water, a counterion, or other non-peptide components. Solution storage time, acceptable freeze-thaw cycles, and filtration recovery should be checked in the actual laboratory method.
How to Read an Ipamorelin COA
A COA is a batch-specific quality record. A proper specification includes the test, the method, and the acceptance limit; it is not just a single HPLC number.[9]
| COA item | Plain-language meaning |
|---|---|
| Identity | Mass spectrometry should show a mass or charge pattern that matches the expected molecule. HPLC retention time alone is not enough to prove identity. |
| Assay / net peptide content | The actual amount of peptide in the as-is material, corrected for water, counterion, and other non-peptide components. The reporting basis (as-is, anhydrous, salt-free, or free-peptide-equivalent) and the method (e.g., quantitative amino acid analysis, calibrated quantitative chromatography, or qNMR) should be stated. This value is needed for accurate molar calculations and cannot be inferred from HPLC area purity alone. |
| HPLC purity | A result such as “≥98% by HPLC” normally means chromatographic area purity under the stated method. It is not the same as net peptide content and does not account for water, counterion, or non-UV-absorbing components. |
| Individual and total related impurities | The COA should report individual impurity peaks above a specified threshold and total related impurities. For ipamorelin, which contains non-proteinogenic residues (Aib, D-2-Nal), relevant impurities may include deletion sequences, truncation sequences, epimers, and stereochemical variants. |
| Water | Water adds to the sample mass and can affect concentration calculations. Karl Fischer testing is commonly used when a specific water result is required. |
| Counterion | TFA, acetate, or another counterion adds mass but is not part of the free-peptide formula. The counterion identity and content should be stated. |
| Residual solvents and reagents | Residual solvents should be measured with a suitable method. Residual coupling reagents, scavengers, or cleavage byproducts from solid-phase peptide synthesis may also be relevant. |
| Aggregates / oligomers | Some HPLC methods may not adequately separate or detect peptide aggregates. When relevant to the assay, an orthogonal method such as size-exclusion chromatography may be needed. |
| Endotoxin / bioburden | Endotoxin and microbiological quality should be considered for animal studies or sensitive cell-based assays. These are not shown by HPLC or mass spectrometry and must be tested separately. |
Analytical methods should be shown to work for their intended purpose. Depending on the test, this may include checks for selectivity, accuracy, precision, range, and robustness.[10] ICH Q3C(R9) provides the main framework for classifying and controlling residual solvents; these principles are written for pharmaceutical development and do not by themselves establish mandatory limits for research-use-only peptides.[13]
Important: HPLC purity or COA conformity does not by itself prove sterility, endotoxin status, biological safety, or suitability for any human or veterinary use.
Authoritative References
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. Oxford Academic.
- National Center for Biotechnology Information. PubChem Compound Summary for Ipamorelin, CID 9831659. NCBI PubChem.
- National Cancer Institute. Ipamorelin. NCI Drug Dictionary. NCI.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PubMed.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PubMed.
- Malagón MM, Luque RM, Ruiz-Guerrero E, Rodríguez-Pacheco F, García-Navarro S, Casanueva FF, Gracia-Navarro F, Castaño JP. Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology. 2003;144(12):5372-5380. doi:10.1210/en.2003-0723. PubMed.
- Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. doi:10.1054/ghir.1999.9998. PubMed.
- Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569-577. PubMed.
- International Council for Harmonisation. ICH Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products. ICH Q6A.
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH Q2(R2).
- Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. doi:10.1023/A:1018955126402. Springer.
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin receptor agonist ipamorelin for the management of postoperative ileus. International Journal of Colorectal Disease. 2014;29(7):849-856. PubMed.
- International Council for Harmonisation. ICH Q3C(R9): Impurities—Guideline for Residual Solvents. ICH Q3C(R9).
- International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. ICH Q1A(R2).
Research Use Only Disclaimer
Research Use Only: The ipamorelin material supplied by SaiyanMed is sold solely as a laboratory research reagent and is not approved by the relevant regulatory authorities as a human or veterinary drug product. No FDA-approved drug product contains ipamorelin free base or ipamorelin acetate.
This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.